RJA
MRNA icon

Raymond James & Associates’s Moderna MRNA Stock Holding History

Raymond James & Associates’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-15,000
Closed -$143K – 4069
2020
Q4 		$143K Buy
+15,000
New +$1.52M ﹤0.01% 3494

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Raymond James & Associates's MRNA Position: Q3 2024 in Review

Raymond James & Associates increased its Moderna (MRNA) stake by 20% in Q3 2024, buying an estimated $2.45M and bringing the position to 162,074 shares worth $10.8M. The position accounts for 0.01% of the portfolio, ranked #1179.

Raymond James & Associates first reported a position in MRNA in Q1 2019 and has held it in 23 quarters since. The position peaked at $57M in Q3 2021. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Raymond James & Associates held 162,074 shares of Moderna worth $10.8M as of Q3 2024.
  • Raymond James & Associates bought 26,657 Moderna shares in Q3 2024, an estimated $2.45M.
  • Moderna made up 0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1179 holding.
  • Raymond James & Associates first reported a position in Moderna in Q1 2019 and has held it in 23 quarters since.
  • Raymond James & Associates's Moderna position peaked at $57M in Q3 2021.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.